The post 2025 Token Listings Fell Up to 99.9% From Its Peak Valuations appeared on BitcoinEthereumNews.com. Multiple 2025 token listings have fallen 90-99.9% fromThe post 2025 Token Listings Fell Up to 99.9% From Its Peak Valuations appeared on BitcoinEthereumNews.com. Multiple 2025 token listings have fallen 90-99.9% from

2025 Token Listings Fell Up to 99.9% From Its Peak Valuations

  • Multiple 2025 token listings have fallen 90-99.9% from all-time high valuations.
  • RESOLV, COAI, AIA, and SHM each dropped over 99% from peak FDV to current levels.
  • Data from CryptoRank shows new listings face depressed sentiment and performance.

New cryptocurrency listings in 2025 have suffered severe drops from their initial valuations. Data from CryptoRank dated December 29, 2025, reveals that tokens launched this year have experienced drops ranging from 9.9% to 99.9% from their all-time high fully diluted valuations.

The brief hype that accompanied early 2025 launches quickly flipped into depressed market sentiment. This downturn has weighed heavily on new token performance, with most projects trading far below initial valuation peaks.

Majority of new listings down over 90% from peaks

RESOLV posted the steepest decline, falling 99.9% from an all-time high FDV of $103 billion to a current valuation of $773 million. SHM followed a similar move, dropping 99.9% from $22 billion at peak to $111 million currently.

COAI experienced a 99% decline, with FDV falling from $35.4 billion to just $3.9 million. AIA also dropped 99%, moving from $28 billion at launch to $110 million at present. These four tokens are the worst performers among 2025 listings tracked by CryptoRank.

PI and TRUMP both declined 93% from their all-time high valuations. PI fell from $20 billion FDV to $3 billion, while TRUMP dropped from $17 billion to $3 billion. DHN recorded a 91% decline, falling from $29 billion to $3 billion in current valuation.

Mid-tier declines still reach double-digit percentages

ATLA experienced a 59% drop from its peak FDV of $72 billion to $31.9 billion currently. WLFI posted a 58% decline, moving from $34 billion at an all-time high to $14 billion at present. These tokens performed better than peers but still face losses exceeding 50%.

RST recorded the smallest drop among tracked listings at 9.9%, with FDV falling from $32 billion to current levels around $28.8 billion. This token stands as an outlier among 2025 launches, maintaining most of its initial valuation through year-end.

The chart comparison between ATH FDV and current FDV shows the widespread weakness affecting new token listings. Most projects launched with high valuations that quickly collapsed as market enthusiasm faded. The pattern suggests investors became increasingly cautious about newly launched tokens throughout 2025.

Related: What Prices to Expect for XRP, BTC, ETH, and ADA on Christmas?

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

Source: https://coinedition.com/2025-token-listings-fell-up-to-99-9-from-its-peak-valuations/

Market Opportunity
TokenFi Logo
TokenFi Price(TOKEN)
$0,004793
$0,004793$0,004793
-%6,27
USD
TokenFi (TOKEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.